Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer.

J R Sainsbury, A J Malcolm, D R Appleton, J R Farndon, A L Harris

Epidermal growth factor receptors are present in some breast cancers in man, and there is an inverse relation to oestrogen receptor state. We assessed the presence of epidermal growth factor receptors as a single prognostic indicator in a series of breast tumours by comparing this with the Bloom and Richardson scores for these tumours. One hundred and eight ductal tumours were examined for epidermal growth factor receptors by radioligand binding. There was a significant (p less than 0.01) correlation between the presence of the growth factor receptor and poor prognosis as assessed by the Bloom and Richardson score, suggesting that epidermal growth factor receptor state could be a useful prognostic marker. Epidermal growth factor receptor state was not significantly correlated with the lymph node state but showed a tendency to be associated with large tumours.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Burris, H. A. III, Taylor, C. W., Jones, S. F., Koch, K. M., Versola, M. J., Arya, N., Fleming, R. A., Smith, D. A., Pandite, L., Spector, N., Wilding, G. (2009). A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies. Clin. Cancer Res. 15: 6702-6708 [Abstract] [Full Text]  
• Chu, Q. S.C., Cianfrocca, M. E., Goldstein, L. J., Gale, M., Murray, N., Loftiss, J., Arya, N., Koch, K. M., Pandite, L., Fleming, R. A., Paul, E., Rowinsky, E. K. (2008). A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer. Clin. Cancer Res. 14: 4484-4490 [Abstract] [Full Text]  
• Chu, Q. S.C., Schwartz, G., de Bono, J., Smith, D. A., Koch, K. M., Versola, M. J., Pandite, L., Arya, N., Curtright, J., Fleming, R. A., Ho, P. T.C., Rowinsky, E. K. (2007). Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies. JCO 25: 3753-3758 [Abstract] [Full Text]  
• Siegel-Lakhai, W. S., Beijnen, J. H., Vervenne, W. L., Boot, H., Keessen, M., Versola, M., Koch, K. M., Smith, D. A., Pandite, L., Richel, D. J., Schellens, J. H.M. (2007). Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors. Clin. Cancer Res. 13: 4495-4502 [Abstract] [Full Text]  
• Silva, C. M., Shupnik, M. A. (2007). Integration of Steroid and Growth Factor Pathways in Breast Cancer: Focus on Signal Transducers and Activators of Transcription and Their Potential Role in Resistance. Mol. Endocrinol. 21: 1499-1512 [Abstract] [Full Text]  
• Zinner, R. G., Nemunaitis, J., Eiseman, I., Shin, H. J. C., Olson, S. C., Christensen, J., Huang, X., Lenehan, P. F., Donato, N. J., Shin, D. M. (2007). Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer. Clin. Cancer Res. 13: 3006-3014 [Abstract] [Full Text]  
• Burris, H. A. III, Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., Harris, J. L., Smith, D. A., Koch, K. M., Stead, A., Mangum, S., Spector, N. L. (2005). Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas. JCO 23: 5305-5313 [Abstract] [Full Text]  
• Wakeling, A E (2005). Inhibitors of growth factor signalling. Endocr Relat Cancer 12: S183-S187 [Abstract] [Full Text]  
• McKillop, D., Partridge, E. A., Kemp, J. V., Spence, M. P., Kendrew, J., Barnett, S., Wood, P. G., Giles, P. B., Patterson, A. B., Bichat, F., Guilbaud, N., Stephens, T. C. (2005). Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics 4: 641-649 [Abstract] [Full Text]  
• Calvo, E., Tolcher, A. W., Hammond, L. A., Patnaik, A., de Bono, J. S., Eiseman, I. A., Olson, S. C., Lenehan, P. F., McCreery, H., LoRusso, P., Rowinsky, E. K. (2004). Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study. Clin. Cancer Res. 10: 7112-7120 [Abstract] [Full Text]  
• Rhee, J. C., Khuri, F. R., Shin, D. M. (2004). Advances in Chemoprevention of Head and Neck Cancer. The Oncologist 9: 302-311 [Abstract] [Full Text]  
• Kloth, M. T., Laughlin, K. K., Biscardi, J. S., Boerner, J. L., Parsons, S. J., Silva, C. M. (2003). STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor. J. Biol. Chem. 278: 1671-1679 [Abstract] [Full Text]  
• Perez, E. A., Geeraerts, L., Suman, V. J., Adjei, A. A., Baron, A. T., Hatfield, A. K., Maihle, N., Michalak, J. C., Kuross, S. A., Kugler, J. W., Lafky, J. M., Ingle, J. N. (2002). A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol 13: 1225-1235 [Abstract] [Full Text]  
• Kloth, M. T., Catling, A. D., Silva, C. M. (2002). Novel Activation of STAT5b in Response to Epidermal Growth Factor. J. Biol. Chem. 277: 8693-8701 [Abstract] [Full Text]  
• Baron, A. T., Lafky, J. M., Suman, V. J., Hillman, D. W., Buenafe, M. C., Boardman, C. H., Podratz, K. C., Perez, E. A., Maihle, N. J. (2001). A Preliminary Study of Serum Concentrations of Soluble Epidermal Growth Factor Receptor (sErbB1), Gonadotropins, and Steroid Hormones in Healthy Men and Women. Cancer Epidemiol. Biomarkers Prev. 10: 1175-1185 [Abstract] [Full Text]  
• Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J. C., Wu, J. Y., Zhang, P., Lawhorn, K., Khuri, F. R., Glisson, B. S., Myers, J., Clayman, G., Pfister, D., Falcey, J., Waksal, H., Mendelsohn, J., Hong, W. K. (2001). Epidermal Growth Factor Receptor-targeted Therapy with C225 and Cisplatin in Patients with Head and Neck Cancer. Clin. Cancer Res. 7: 1204-1213 [Abstract] [Full Text]  
• Salvatori, L., Ravenna, L., Felli, M. P., Cardillo, M. R., Russo, M. A., Frati, L., Gulino, A., Petrangeli, E. (2000). Identification of an Estrogen-Mediated Deoxyribonucleic Acid-Binding Independent Transactivation Pathway on the Epidermal Growth Factor Receptor Gene Promoter. Endocrinology 141: 2266-2274 [Abstract] [Full Text]  
• Mendelsohn, J. (2000). Blockade of Receptors for Growth Factors: An Anticancer Therapy -- The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. 6: 747-753 [Full Text]  
• Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., Vaidya, M. P., Arnold, L. D., Doty, J. L., Iwata, K. K., Morin, M. J. (1999). Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice. J. Pharmacol. Exp. Ther. 291: 739-748 [Abstract] [Full Text]  
• Baron, A. T., Lafky, J. M., Boardman, C. H., Balasubramaniam, S., Suman, V. J., Podratz, K. C., Maihle, N. J. (1999). Serum sErbB1 and Epidermal Growth Factor Levels As Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer. Cancer Epidemiol. Biomarkers Prev. 8: 129-137 [Abstract] [Full Text]  
• Gohring, U. J., Ahr, A., Scharl, A., Weisner, V., Neuhaus, W., Crombach, G., Holt, J. A. (1995). Immunohistochemical Detection of Epidermal Growth Factor Receptor Lacks Prognostic Significance for Breast Carcinoma. Reproductive Sciences 2: 653-659 [Abstract]